Aslan Pharmaceuticals Initiates Third Dose Cohort Of ASLAN004 In Atopic Dermatitis Clinical Trial; ASLAN004 Found To Be Well Tolerated At 400mg Dose, Third Cohort Will Test 600mg Dose